vs
Aclaris Therapeutics, Inc.（ACRS）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Aclaris Therapeutics, Inc.的1760.2倍（$2.3B vs $1.3M）。渤健净利率更高（-2.1% vs -1528.6%，领先1526.4%）。渤健同比增速更快（-7.1% vs -85.9%）。渤健自由现金流更多（$468.0M vs $-13.2M）。过去两年渤健的营收复合增速更高（-0.2% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
ACRS vs BIIB — 直观对比
营收规模更大
BIIB
是对方的1760.2倍
$1.3M
营收增速更快
BIIB
高出78.8%
-85.9%
净利率更高
BIIB
高出1526.4%
-1528.6%
自由现金流更多
BIIB
多$481.2M
$-13.2M
两年增速更快
BIIB
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $2.3B |
| 净利润 | $-19.8M | $-48.9M |
| 毛利率 | 58.9% | 78.3% |
| 营业利润率 | -1755.5% | -2.5% |
| 净利率 | -1528.6% | -2.1% |
| 营收同比 | -85.9% | -7.1% |
| 净利润同比 | 79.5% | -118.3% |
| 每股收益（稀释后） | $-0.16 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSBIIB
| Q4 25 | $1.3M | $2.3B | ||
| Q3 25 | $3.3M | $2.5B | ||
| Q2 25 | $1.8M | $2.6B | ||
| Q1 25 | $1.5M | $2.4B | ||
| Q4 24 | $9.2M | $2.5B | ||
| Q3 24 | $4.3M | $2.5B | ||
| Q2 24 | $2.8M | $2.5B | ||
| Q1 24 | $2.4M | $2.3B |
净利润ACRSBIIB
| Q4 25 | $-19.8M | $-48.9M | ||
| Q3 25 | $-14.6M | $466.5M | ||
| Q2 25 | $-15.4M | $634.8M | ||
| Q1 25 | $-15.1M | $240.5M | ||
| Q4 24 | $-96.6M | $266.7M | ||
| Q3 24 | $-7.6M | $388.5M | ||
| Q2 24 | $-11.0M | $583.6M | ||
| Q1 24 | $-16.9M | $393.4M |
毛利率ACRSBIIB
| Q4 25 | 58.9% | 78.3% | ||
| Q3 25 | 83.7% | 73.4% | ||
| Q2 25 | 71.0% | 77.1% | ||
| Q1 25 | 65.2% | 74.1% | ||
| Q4 24 | 92.3% | 76.2% | ||
| Q3 24 | 85.0% | 74.1% | ||
| Q2 24 | 77.4% | 77.8% | ||
| Q1 24 | 66.3% | 76.3% |
营业利润率ACRSBIIB
| Q4 25 | -1755.5% | -2.5% | ||
| Q3 25 | -519.8% | 22.0% | ||
| Q2 25 | -1035.9% | 28.1% | ||
| Q1 25 | -1242.9% | 12.8% | ||
| Q4 24 | -1082.3% | 11.9% | ||
| Q3 24 | -240.9% | 18.3% | ||
| Q2 24 | -464.7% | 28.3% | ||
| Q1 24 | -789.4% | 20.3% |
净利率ACRSBIIB
| Q4 25 | -1528.6% | -2.1% | ||
| Q3 25 | -443.0% | 18.4% | ||
| Q2 25 | -868.3% | 24.0% | ||
| Q1 25 | -1036.8% | 9.9% | ||
| Q4 24 | -1048.3% | 10.9% | ||
| Q3 24 | -174.6% | 15.8% | ||
| Q2 24 | -397.2% | 23.7% | ||
| Q1 24 | -706.5% | 17.2% |
每股收益（稀释后）ACRSBIIB
| Q4 25 | $-0.16 | $-0.35 | ||
| Q3 25 | $-0.12 | $3.17 | ||
| Q2 25 | $-0.13 | $4.33 | ||
| Q1 25 | $-0.12 | $1.64 | ||
| Q4 24 | $-1.21 | $1.82 | ||
| Q3 24 | $-0.11 | $2.66 | ||
| Q2 24 | $-0.15 | $4.00 | ||
| Q1 24 | $-0.24 | $2.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $103.1M | $18.3B |
| 总资产 | $160.5M | $29.4B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资ACRSBIIB
| Q4 25 | $20.0M | — | ||
| Q3 25 | $25.3M | — | ||
| Q2 25 | $25.4M | — | ||
| Q1 25 | $30.4M | — | ||
| Q4 24 | $24.6M | — | ||
| Q3 24 | $47.7M | — | ||
| Q2 24 | $22.8M | — | ||
| Q1 24 | $35.8M | — |
总债务ACRSBIIB
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.3B |
股东权益ACRSBIIB
| Q4 25 | $103.1M | $18.3B | ||
| Q3 25 | $120.1M | $18.2B | ||
| Q2 25 | $131.7M | $17.6B | ||
| Q1 25 | $144.1M | $17.0B | ||
| Q4 24 | $155.6M | $16.7B | ||
| Q3 24 | $130.2M | $16.4B | ||
| Q2 24 | $133.8M | $15.9B | ||
| Q1 24 | $142.0M | $15.2B |
总资产ACRSBIIB
| Q4 25 | $160.5M | $29.4B | ||
| Q3 25 | $175.5M | $29.2B | ||
| Q2 25 | $189.1M | $28.3B | ||
| Q1 25 | $198.1M | $28.0B | ||
| Q4 24 | $220.3M | $28.0B | ||
| Q3 24 | $182.4M | $28.3B | ||
| Q2 24 | $161.1M | $26.8B | ||
| Q1 24 | $174.1M | $26.6B |
负债/权益比ACRSBIIB
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | $511.9M |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | $468.0M |
| 自由现金流率自由现金流/营收 | -1015.8% | 20.5% |
| 资本支出强度资本支出/营收 | 1.9% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-47.2M | $2.1B |
8季度趋势，按日历期对齐
经营现金流ACRSBIIB
| Q4 25 | $-13.1M | $511.9M | ||
| Q3 25 | $-10.9M | $1.3B | ||
| Q2 25 | $-10.0M | $160.9M | ||
| Q1 25 | $-13.1M | $259.3M | ||
| Q4 24 | $-8.9M | $760.9M | ||
| Q3 24 | $22.0M | $935.6M | ||
| Q2 24 | $-12.3M | $625.8M | ||
| Q1 24 | $-20.8M | $553.2M |
自由现金流ACRSBIIB
| Q4 25 | $-13.2M | $468.0M | ||
| Q3 25 | $-11.0M | $1.2B | ||
| Q2 25 | $-10.0M | $134.3M | ||
| Q1 25 | $-13.1M | $222.2M | ||
| Q4 24 | — | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | $-12.3M | $592.3M | ||
| Q1 24 | $-20.9M | $507.3M |
自由现金流率ACRSBIIB
| Q4 25 | -1015.8% | 20.5% | ||
| Q3 25 | -332.1% | 48.4% | ||
| Q2 25 | -563.5% | 5.1% | ||
| Q1 25 | -900.3% | 9.1% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | -446.0% | 24.0% | ||
| Q1 24 | -873.6% | 22.1% |
资本支出强度ACRSBIIB
| Q4 25 | 1.9% | 1.9% | ||
| Q3 25 | 0.7% | 1.8% | ||
| Q2 25 | 1.2% | 1.0% | ||
| Q1 25 | 3.0% | 1.5% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 5.6% | 2.0% |
现金转化率ACRSBIIB
| Q4 25 | — | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.07× | ||
| Q1 24 | — | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRS
暂无分部数据
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
